The hospital acquired infections testing kits market size has grown strongly in recent years. It will grow from $4.79 billion in 2025 to $5.19 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing hospital infection surveillance, rising prevalence of antibiotic-resistant pathogens, expansion of clinical microbiology labs, implementation of infection control protocols, availability of molecular diagnostic tools.
The hospital acquired infections testing kits market size is expected to see strong growth in the next few years. It will grow to $7.2 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing focus on early infection detection, rising investments in hospital safety infrastructure, expansion of rapid testing adoption, growing demand for automated diagnostic workflows, advancements in molecular diagnostics technology. Major trends in the forecast period include increasing adoption of rapid diagnostic test kits, rising use of molecular testing for hais, growing integration of automated diagnostic instruments, expansion of point-of-care infection testing, enhanced focus on multi-pathogen detection.
The increasing number of healthcare settings is anticipated to drive the growth of the hospital-acquired infections testing kits market in the coming years. A healthcare setting encompasses a range of facilities and services, including acute care hospitals, urgent care centers, rehabilitation facilities, nursing homes, and long-term care facilities, collectively delivering comprehensive healthcare solutions. Hospital-acquired infections testing kits serve as essential tools for identifying and preventing nosocomial infections, thereby improving patient safety across healthcare facilities. For example, in May 2023, according to the American Hospital Association, a US-based healthcare industry trade group, the total number of hospitals in the U.S. region increased significantly from 6,093 in 2022 to 60,129 in 2023. In addition, admissions in community hospitals also rose, increasing from 31,393,318 in 2022 to 31,967,073 in 2023. Consequently, the growing number of healthcare settings is fueling the hospital-acquired infections testing kits market.
The rising number of surgical procedures is expected to drive growth in the hospital-acquired infections testing kits market. Surgical procedures are medical operations performed in operating theaters that involve incision, excision, or tissue manipulation, typically requiring regional or general anesthesia or profound sedation to manage pain. The increase in surgical procedures is largely driven by an aging population, as older adults require more medical interventions for age-related conditions and chronic diseases. Higher surgical volumes increase demand for testing kits, as surgeries create entry points for pathogens, raising the risk of infections that require systematic detection and monitoring through specialized diagnostic tools. For example, in May 2025, the Australian Institute of Health and Welfare, an Australia-based government agency providing health and welfare statistics, reported that hospitalizations involving surgery rose from 3 million in 2022-23 to 3.1 million in 2023-24, an increase of 100,000 cases. This rise in surgical procedures is therefore driving growth in the hospital-acquired infections testing kits market.
Major companies in the hospital-acquired infections (HAI) testing kits market are focusing on developing advanced point-of-care antimicrobial susceptibility testing (AST) solutions to enable rapid diagnosis, guide targeted therapy, and address antimicrobial resistance (AMR). Point-of-care AST uses proprietary microfluidic technology to quickly detect bacterial presence and assess antibiotic effectiveness directly from patient urine samples, reducing diagnostic delays and improving treatment decisions. For example, in June 2023, Sysmex Corporation, a Japan-based diagnostics company, launched the world’s first point-of-care testing system in Europe capable of performing antimicrobial susceptibility testing in just 30 minutes. Using a microfluidic-based AST approach for patients suspected of urinary tract infections, the system significantly shortens turnaround time and supports antimicrobial stewardship in primary care by enabling timely and informed antibiotic use, contributing to global efforts to combat AMR.
Major companies operating in the hospital acquired infections testing kits market are Becton Dickinson and Company, Abbott Laboratories, Cepheid, F. Hoffmann-La Roche Ltd, STERIS plc, QIAGEN, Meridian Bioscience Inc., BioMérieux SA, GE Healthcare, Seegene, SD Biosensor, Fujirebio, Sysmex Corporation, Getein Biotech, Hangzhou Biotest Biotech, AmonMed Biotechnology, Beijing Tigsun Diagnostics, Hunan Lituo Biotechnology, ImmunoScience, Vivacheck Lab.
North America was the largest region in the hospital-acquired infections testing kits market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hospital acquired infections testing kits market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hospital acquired infections testing kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the hospital acquired infections testing kits market by increasing costs of imported reagents, molecular assay kits, diagnostic instruments, and electronic components. Healthcare facilities in North America and Europe are most affected due to dependence on imported testing supplies, while Asia-Pacific faces export-related pricing pressures. These tariffs are increasing testing costs and procurement challenges for hospitals. However, they are also encouraging local manufacturing of consumables, regional reagent production, and strengthened domestic diagnostic supply chains.
The hospital acquired infections testing kits market research report is one of a series of new reports that provides hospital acquired infections testing kits market statistics, including hospital acquired infections testing kits industry global market size, regional shares, competitors with a hospital acquired infections testing kits market share, detailed hospital acquired infections testing kits market segments, market trends and opportunities, and any further data you may need to thrive in the hospital acquired infections testing kits industry. This hospital acquired infections testing kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hospital-acquired infection testing kits are utilized to examine infections contracted by individuals within a healthcare facility. These kits play a crucial role in identifying infections associated with pathogens such as vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), multi-resistant gram-negative bacilli, norovirus, and Clostridium difficile.
The primary components of hospital-acquired infection testing kits include instruments, reagents, and consumables. Instruments for these testing kits encompass various tools essential for hospital-acquired infections testing, aiding scientists in cultivating new cells in culture media for purposes such as drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing. Hospital-acquired infections testing kits address pathogens such as viruses, bacteria, and fungi through sterilization, chemical treatments, and radiation methods. The testing extends to identifying infections such as pneumonia, urinary tract infection, bloodstream infection, surgical site infection, MRSA infection, and others. These kits find applications in drug-resistance testing and disease testing.
The hospital-acquired infections testing kits market consist of sales of testing kits and devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The hospital acquired infections testing kits market size is expected to see strong growth in the next few years. It will grow to $7.2 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing focus on early infection detection, rising investments in hospital safety infrastructure, expansion of rapid testing adoption, growing demand for automated diagnostic workflows, advancements in molecular diagnostics technology. Major trends in the forecast period include increasing adoption of rapid diagnostic test kits, rising use of molecular testing for hais, growing integration of automated diagnostic instruments, expansion of point-of-care infection testing, enhanced focus on multi-pathogen detection.
The increasing number of healthcare settings is anticipated to drive the growth of the hospital-acquired infections testing kits market in the coming years. A healthcare setting encompasses a range of facilities and services, including acute care hospitals, urgent care centers, rehabilitation facilities, nursing homes, and long-term care facilities, collectively delivering comprehensive healthcare solutions. Hospital-acquired infections testing kits serve as essential tools for identifying and preventing nosocomial infections, thereby improving patient safety across healthcare facilities. For example, in May 2023, according to the American Hospital Association, a US-based healthcare industry trade group, the total number of hospitals in the U.S. region increased significantly from 6,093 in 2022 to 60,129 in 2023. In addition, admissions in community hospitals also rose, increasing from 31,393,318 in 2022 to 31,967,073 in 2023. Consequently, the growing number of healthcare settings is fueling the hospital-acquired infections testing kits market.
The rising number of surgical procedures is expected to drive growth in the hospital-acquired infections testing kits market. Surgical procedures are medical operations performed in operating theaters that involve incision, excision, or tissue manipulation, typically requiring regional or general anesthesia or profound sedation to manage pain. The increase in surgical procedures is largely driven by an aging population, as older adults require more medical interventions for age-related conditions and chronic diseases. Higher surgical volumes increase demand for testing kits, as surgeries create entry points for pathogens, raising the risk of infections that require systematic detection and monitoring through specialized diagnostic tools. For example, in May 2025, the Australian Institute of Health and Welfare, an Australia-based government agency providing health and welfare statistics, reported that hospitalizations involving surgery rose from 3 million in 2022-23 to 3.1 million in 2023-24, an increase of 100,000 cases. This rise in surgical procedures is therefore driving growth in the hospital-acquired infections testing kits market.
Major companies in the hospital-acquired infections (HAI) testing kits market are focusing on developing advanced point-of-care antimicrobial susceptibility testing (AST) solutions to enable rapid diagnosis, guide targeted therapy, and address antimicrobial resistance (AMR). Point-of-care AST uses proprietary microfluidic technology to quickly detect bacterial presence and assess antibiotic effectiveness directly from patient urine samples, reducing diagnostic delays and improving treatment decisions. For example, in June 2023, Sysmex Corporation, a Japan-based diagnostics company, launched the world’s first point-of-care testing system in Europe capable of performing antimicrobial susceptibility testing in just 30 minutes. Using a microfluidic-based AST approach for patients suspected of urinary tract infections, the system significantly shortens turnaround time and supports antimicrobial stewardship in primary care by enabling timely and informed antibiotic use, contributing to global efforts to combat AMR.
Major companies operating in the hospital acquired infections testing kits market are Becton Dickinson and Company, Abbott Laboratories, Cepheid, F. Hoffmann-La Roche Ltd, STERIS plc, QIAGEN, Meridian Bioscience Inc., BioMérieux SA, GE Healthcare, Seegene, SD Biosensor, Fujirebio, Sysmex Corporation, Getein Biotech, Hangzhou Biotest Biotech, AmonMed Biotechnology, Beijing Tigsun Diagnostics, Hunan Lituo Biotechnology, ImmunoScience, Vivacheck Lab.
North America was the largest region in the hospital-acquired infections testing kits market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hospital acquired infections testing kits market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hospital acquired infections testing kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the hospital acquired infections testing kits market by increasing costs of imported reagents, molecular assay kits, diagnostic instruments, and electronic components. Healthcare facilities in North America and Europe are most affected due to dependence on imported testing supplies, while Asia-Pacific faces export-related pricing pressures. These tariffs are increasing testing costs and procurement challenges for hospitals. However, they are also encouraging local manufacturing of consumables, regional reagent production, and strengthened domestic diagnostic supply chains.
The hospital acquired infections testing kits market research report is one of a series of new reports that provides hospital acquired infections testing kits market statistics, including hospital acquired infections testing kits industry global market size, regional shares, competitors with a hospital acquired infections testing kits market share, detailed hospital acquired infections testing kits market segments, market trends and opportunities, and any further data you may need to thrive in the hospital acquired infections testing kits industry. This hospital acquired infections testing kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hospital-acquired infection testing kits are utilized to examine infections contracted by individuals within a healthcare facility. These kits play a crucial role in identifying infections associated with pathogens such as vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), multi-resistant gram-negative bacilli, norovirus, and Clostridium difficile.
The primary components of hospital-acquired infection testing kits include instruments, reagents, and consumables. Instruments for these testing kits encompass various tools essential for hospital-acquired infections testing, aiding scientists in cultivating new cells in culture media for purposes such as drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing. Hospital-acquired infections testing kits address pathogens such as viruses, bacteria, and fungi through sterilization, chemical treatments, and radiation methods. The testing extends to identifying infections such as pneumonia, urinary tract infection, bloodstream infection, surgical site infection, MRSA infection, and others. These kits find applications in drug-resistance testing and disease testing.
The hospital-acquired infections testing kits market consist of sales of testing kits and devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Hospital Acquired Infections Testing Kits Market Characteristics
3. Hospital Acquired Infections Testing Kits Market Supply Chain Analysis
4. Global Hospital Acquired Infections Testing Kits Market Trends and Strategies
5. Hospital Acquired Infections Testing Kits Market Analysis of End Use Industries
7. Global Hospital Acquired Infections Testing Kits Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Hospital Acquired Infections Testing Kits Total Addressable Market (TAM) Analysis for the Market
9. Hospital Acquired Infections Testing Kits Market Segmentation
10. Hospital Acquired Infections Testing Kits Market Regional and Country Analysis
11. Asia-Pacific Hospital Acquired Infections Testing Kits Market
12. China Hospital Acquired Infections Testing Kits Market
13. India Hospital Acquired Infections Testing Kits Market
14. Japan Hospital Acquired Infections Testing Kits Market
15. Australia Hospital Acquired Infections Testing Kits Market
16. Indonesia Hospital Acquired Infections Testing Kits Market
17. South Korea Hospital Acquired Infections Testing Kits Market
18. Taiwan Hospital Acquired Infections Testing Kits Market
19. South East Asia Hospital Acquired Infections Testing Kits Market
20. Western Europe Hospital Acquired Infections Testing Kits Market
21. UK Hospital Acquired Infections Testing Kits Market
22. Germany Hospital Acquired Infections Testing Kits Market
23. France Hospital Acquired Infections Testing Kits Market
24. Italy Hospital Acquired Infections Testing Kits Market
25. Spain Hospital Acquired Infections Testing Kits Market
26. Eastern Europe Hospital Acquired Infections Testing Kits Market
27. Russia Hospital Acquired Infections Testing Kits Market
28. North America Hospital Acquired Infections Testing Kits Market
29. USA Hospital Acquired Infections Testing Kits Market
30. Canada Hospital Acquired Infections Testing Kits Market
31. South America Hospital Acquired Infections Testing Kits Market
32. Brazil Hospital Acquired Infections Testing Kits Market
33. Middle East Hospital Acquired Infections Testing Kits Market
34. Africa Hospital Acquired Infections Testing Kits Market
36. Hospital Acquired Infections Testing Kits Market Competitive Landscape and Company Profiles
37. Hospital Acquired Infections Testing Kits Market Other Major and Innovative Companies
40. Hospital Acquired Infections Testing Kits Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Hospital Acquired Infections Testing Kits Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses hospital acquired infections testing kits market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hospital acquired infections testing kits? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hospital acquired infections testing kits market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Consumables And Reagents; Instruments2) By Test Type: Pneumoia Infection; Urinary Track Infection; Blood Stream Associated Infection; Surgical Site Infection; MRSA infection; Others
3) By Pathogen Type: Viral; Bacterial; Fungal
4) By Application: Drug Resistance Testing; Disease Testing
Subsegments:
1) By Consumables and Reagents: Culture Media (Used for isolating and identifying pathogens); Reagents For Molecular Testing (Includes PCR reagents and kits for detecting specific pathogens); Test Kits (Rapid tests and other kits designed for various infections); Other Consumables (Includes swabs, sample collection devices, and preservation solutions)2) By Instruments: Automated Analyzers (Equipment used for blood culture analysis and identification of pathogens); Molecular Diagnostic Instruments (Machines used for PCR and other molecular testing methods); Microscopes (Used for the identification of pathogens in samples); Incubators And Growth Chambers (For culturing samples under controlled conditions)
Companies Mentioned: Becton Dickinson and Company; Abbott Laboratories; Cepheid; F. Hoffmann-La Roche Ltd; STERIS plc; QIAGEN; Meridian Bioscience Inc.; BioMérieux SA; GE Healthcare; Seegene; SD Biosensor; Fujirebio; Sysmex Corporation; Getein Biotech; Hangzhou Biotest Biotech; AmonMed Biotechnology; Beijing Tigsun Diagnostics; Hunan Lituo Biotechnology; ImmunoScience; Vivacheck Lab
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Hospital Acquired Infections Testing Kits market report include:- Becton Dickinson and Company
- Abbott Laboratories
- Cepheid
- F. Hoffmann-La Roche Ltd
- STERIS plc
- QIAGEN
- Meridian Bioscience Inc.
- BioMérieux SA
- GE Healthcare
- Seegene
- SD Biosensor
- Fujirebio
- Sysmex Corporation
- Getein Biotech
- Hangzhou Biotest Biotech
- AmonMed Biotechnology
- Beijing Tigsun Diagnostics
- Hunan Lituo Biotechnology
- ImmunoScience
- Vivacheck Lab
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.19 Billion |
| Forecasted Market Value ( USD | $ 7.2 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
